dr. grothey on biomarkers to inform metastatic crc treatment decisions
Published 3 years ago • 90 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
1:35
dr. axel grothey on bevacizumab beyond progression in metastatic colorectal cancer
-
11:50
colon cancer management - dr. axel grothey, part 1
-
8:54
debate: do biomarkers have a role in the adjuvant setting? - no
-
4:52
the role of biomarkers in colorectal cancer
-
1:55
dr. grothey describes the phase iii correct study
-
44:47
biomarker driven treatment of metastatic colorectal cancer
-
1:00:00
optimizing biomarker testing to guide treatment selection for metastatic colorectal cancer
-
1:27
dr. grothey on fda approval of pembrolizumab in msi-high crc
-
8:35
colorectal cancer and the correct trial - interview with axel grothey, md, at asco 2012
-
34:17
colorectal cancer breakout: biomarkers for effective treatment
-
3:02
final thoughts on the treatment of metastatic colorectal cancer
-
1:12
dr. lenz on choosing between regorafenib and tas-102 in crc
-
2:03
dr. axel grothey on the side effect profile of regorafenib in metastatic colorectal cancer
-
22:46
mutational testing and the treatment of colorectal cancer
-
29:15
icaho20 - asco direct™ highlights - dr. axel grothey - colorectal cancer
-
55:07
biomarkers and biomarker testing: all you need to know - sept 2017 webinar
-
24:52
icaho 2017 - dr. axel grothey
-
6:17
colorectal cancer & ctdna updates with dr. axel grothey
-
2:23
biomarker testing and targeted therapies in colorectal cancer